Cargando…
Hypermethylation of the SEPT9 Gene Suggests Significantly Poor Prognosis in Cancer Patients: A Systematic Review and Meta-Analysis
Background: Aberrant hypermethylation of the Septin 9 (SEPT9) is an early event in several human cancers, and increasing studies have reported good performance of methylated SEPT9 (mSEPT9) in cancer diagnosis. Recent studies further focused on its value in cancer prognosis, but results are not clear...
Autores principales: | Shen, Na, Wang, Ting, Li, Delei, Zhu, Yaowu, Xie, Huaping, Lu, Yanjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761278/ https://www.ncbi.nlm.nih.gov/pubmed/31608117 http://dx.doi.org/10.3389/fgene.2019.00887 |
Ejemplares similares
-
Performance Comparison Between Plasma and Stool Methylated SEPT9 Tests for Detecting Colorectal Cancer
por: Liu, Yi, et al.
Publicado: (2020) -
Aberrant DNA Methylation of SEPT9 and SDC2 in Stool Specimens as an Integrated Biomarker for Colorectal Cancer Early Detection
por: Zhao, Guodong, et al.
Publicado: (2020) -
TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma
por: Gao, Wen, et al.
Publicado: (2022) -
Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract
por: Branchi, V., et al.
Publicado: (2016) -
Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis
por: Hu, Jincui, et al.
Publicado: (2019)